Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 109.625 -0.115 (-0.1%) Market Cap: 6.91 Bil Enterprise Value: 10.90 Bil PE Ratio: 22.60 PB Ratio: 1.87 GF Score: 78/100

Jazz Pharmaceuticals PLC at JPMorgan NAPA Valley Forum (Virtual) Transcript

Mar 29, 2021 / 04:00PM GMT
Release Date Price: $167.52 (-0.53%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Welcome back, everyone, as we continue the 2021 JPMorgan Virtual Napa Valley Biotech Forum. We're continuing the day sessions with Jazz, and I'm joined by a number of members of the management team, including the company's Chairman and CEO, Bruce Cozadd; Head of R&D and Chief Medical Officer, Robert Iannone; Chief Operating Officer, Dan Swisher; as well as Andrea Flynn, who heads up IR. (Operator Instructions)

You can use that as the session is going to send any questions through the portal, I can ask them to management. There's a little lag on that. So feel free to just send them as you think of them while we're going, and then I'll ask management.

So before we get into Q&A, Bruce, maybe you can just start with a couple of opening comments to kind of frame the conversation, and we can take it from there.

Bruce C. Cozadd
Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO

Yes. So Jess, great to be with you. And Dan, Rob and I are really excited

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot